Literature DB >> 2582053

Distinct proliferative T cell clonotypes are generated in response to a murine retrovirus-induced syngeneic T cell leukemia: viral gp70 antigen-specific MT4+ clones and Lyt-2+ cytolytic clones which recognize a tumor-specific cell surface antigen.

L A Matis, S K Ruscetti, D L Longo, S Jacobson, E J Brown, S Zinn, A M Kruisbeek.   

Abstract

After immunization of B6 mice with the syngeneic retrovirus-induced T cell leukemia/lymphoma FBL-3, two major tumor-specific proliferative T cell clonotypes were derived. T cell clones derived from long-term lines propagated by in vitro culture with irradiated tumor cells and syngeneic spleen cells were exclusively of the Lyt-2+ phenotype. Such clones were cytolytic, retained their proliferative phenotype indefinitely when expanded by repeated cycles of reactivation and rest, and recognized a tumor-specific cell surface antigen in association with class I MHC molecules. This tumor cell antigen was not present on nontransformed virus-infected cells. Class II MHC-restricted MT4+ clones specific for the viral antigen gp70 were derived from lymph node T cells of FBL-3 tumor-immune mice only by in vitro culture with purified Friend virus in the presence of syngeneic splenic APC. Once derived, however, such clones could be stimulated in the presence of FBL-3 tumor cells and syngeneic spleen cells, demonstrating the reprocessing of tumor-derived gp70 antigen by APC in the spleen cell population. In contrast, no reprocessing of the tumor cell surface antigen by splenic APC for presentation to the class I MHC-restricted T cell clones could be demonstrated. Evidence is presented that FBL-3 T leukemia/lymphoma cells function as APC for Lyt-2+ class I MHC-restricted clones, and that no concomitant recognition of Ia molecules is required to activate these clones. Both Lyt-2+ and MT4+ clones were induced to proliferate in the presence of exogenous IL2 alone, but this stimulus failed to result in significant release of immune interferon. In contrast, antigen stimulation of both clones resulted in proliferation as well as significant immune interferon release. Immune interferon production is not required for the generation of MHC-restricted cell-mediated cytolytic function.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2582053

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Immunogenic determinants of a neuropathogenic murine leukemia virus.

Authors:  D S Robbins; M P Remington; M Sarzotti; D St Louis; P M Hoffman
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

2.  Multiplicity of virus-encoded helper T-cell epitopes expressed on FBL-3 tumor cells.

Authors:  M Iwashiro; T Kondo; T Shimizu; H Yamagishi; K Takahashi; Y Matsubayashi; T Masuda; A Otaka; N Fujii; A Ishimoto
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

3.  Protective cellular retroviral immunity requires both CD4+ and CD8+ immune T cells.

Authors:  R C Hom; R W Finberg; S Mullaney; R M Ruprecht
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

4.  The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product.

Authors:  A Y Huang; P H Gulden; A S Woods; M C Thomas; C D Tong; W Wang; V H Engelhard; G Pasternack; R Cotter; D Hunt; D M Pardoll; E M Jaffee
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

5.  FBL-reactive CD8+ cytotoxic and CD4+ helper T lymphocytes recognize distinct Friend murine leukemia virus-encoded antigens.

Authors:  J P Klarnet; D E Kern; K Okuno; C Holt; F Lilly; P D Greenberg
Journal:  J Exp Med       Date:  1989-02-01       Impact factor: 14.307

6.  Generation of diversity in T cell receptor repertoire specific for pigeon cytochrome c.

Authors:  S B Sorger; S M Hedrick; P J Fink; M A Bookman; L A Matis
Journal:  J Exp Med       Date:  1987-02-01       Impact factor: 14.307

7.  Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells.

Authors:  M A Cheever; D B Thompson; J P Klarnet; P D Greenberg
Journal:  J Exp Med       Date:  1986-05-01       Impact factor: 14.307

8.  The roles of CD8+ and CD4+ cells in tumor rejection.

Authors:  H Udono; M Mieno; H Shiku; E Nakayama
Journal:  Jpn J Cancer Res       Date:  1989-07

9.  Interleukin 7 promotes long-term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo.

Authors:  D H Lynch; R E Miller
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

10.  Enhancement of anti-tumor activity of natural killer cells by BALL-1, a B cell lymphoma line.

Authors:  M Hirashima; N Yoshida; M Seki; H Okada; S Takamura; Y Mihara
Journal:  Jpn J Cancer Res       Date:  1998-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.